KRAS and non-small cell lung carcinoma: Our study showed the median overall survival (mOS) of KRAS-mutant advanced NSCLC patients as 22.9 months (95% CI: 14.07–31.67) and the median progression-free survival (mPFS) as 9.4 months (95% CI: 6.60–12.14) (Figures 2A, , B).